来源：市场投研资讯 （来源：预审IPO） 文/瑞财经 李姗姗 2007年的夏天，一句"弹弹弹，弹走鱼尾纹"的广告词火遍大江南北，背后的丸美生物（603983.SH）一 举成为国货眼霜市场的先行者。 时至今日，人们仍对这句魔性的广告语记忆深刻，同时，丸美生物也依然站在市场的巅峰。据弗若斯特 沙利文报告，丸美的零售额自2021年至2024年连续四年稳居国内眼部护理品牌第一。 近日，这支A股"眼霜第一股"向港交所递交了招股书，期望实现"A+H"双平台上市。 丸美生物布局资本市场的同时，其背后的孙怀庆家族完成了一次权力交接。2021年3月，孙怀庆的儿子 孙云起从母亲王晓蒲手中接过董事的职位。 目前，丸美生物的实控人依然是孙怀庆、王晓蒲，夫妇二人合计控股80.8%。 赴港IPO前，丸美生物实施了A股上市以来最强分红，作为控股股东，孙怀庆夫妇成为最大的受益者。 01 孙怀庆夫妇控股80.8% 首发募投项目全部延期 丸美生物诞生于重庆人孙怀庆之手。 上世纪90年代，下海创业的浪潮席卷全国，26岁的孙怀庆亦辞掉重庆特种电机厂这一国企"铁饭碗"，南 下广州闯荡，试图在美妆美服领域找到立足之地。 在广州打拼的6年多时间里，孙怀庆 ...

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 1.769 billion yuan for H1 2025, representing a year-on-year increase of 30.83%, while the net profit attributable to the parent company was 186 million yuan, up 5.21% year-on-year [1] - The company is expected to enhance efficiency in the second half of the year following a phase of adjustment in Q2 2025 [1] - The company maintains a strong focus on brand building and innovation, with significant growth in its eye care product line and online sales channels [4] Financial Performance Summary - For H1 2025, the gross margin was 74.60%, a slight decrease of 0.07 percentage points year-on-year, while the net profit margin was 10.50%, down 2.56 percentage points year-on-year [2] - In Q2 2025, the gross margin decreased to 73.28%, down 1.47 percentage points year-on-year, and the net profit margin fell to 5.50%, down 4.04 percentage points year-on-year [2] - The company’s revenue from eye care products reached 420 million yuan in H1 2025, a remarkable increase of 76.18% year-on-year, contributing to 23.75% of total revenue [3] Product and Market Strategy Summary - The company has implemented a big product strategy, successfully launching new products such as the upgraded dual collagen cleansing milk and the super mask, maintaining its position as the leading domestic brand in eye care [4] - The online sales channel accounted for 88.87% of total revenue, with a year-on-year growth of 37.85%, while offline sales decreased by 7.07% [3] - The company’s overall R&D investment for H1 2025 was 40.7 million yuan, with five self-developed core raw materials successfully commercialized [4] Future Outlook - The company expects revenue for 2025-2027 to be 3.856 billion, 4.800 billion, and 5.915 billion yuan respectively, with net profits projected at 430 million, 540 million, and 670 million yuan [4] - The company is positioned to continue its growth trajectory with a focus on both "lifestyle beauty" and "medical beauty" sectors [4]

Company Overview - Shenzhen Weiqi Technology Co., Ltd. (Weiqi Technology) has been accepted for IPO on the Beijing Stock Exchange, with Guosen Securities as the sponsor [2] - Established in 2011, the company has a registered capital of 50 million yuan, focusing on the R&D, production, sales, and related services of cosmetic raw materials and finished products [2] Fundraising and Projects - The company aims to raise 366 million yuan through the IPO, which will be allocated to the construction of the Weiqi Health Industry Park project and the Weiqi Technology R&D Center project [2] Product and Innovation - As of the signing date of the prospectus, Weiqi Technology has 16 cosmetic raw materials approved by the National Medical Products Administration, including 7 innovative raw materials, ranking first in both total and innovative raw material approvals [3] - The company has entered the supply chain of well-known domestic and international brands such as Marubi and Procter & Gamble [3] Ownership Structure - Ding Wenfeng and Lai Yanmin are the actual controllers of Weiqi Technology, collectively holding 62.1% of the shares [4] - Ding Wenfeng directly holds 57.28% of the shares and indirectly controls an additional 1.27% through the employee stock ownership platform, Weijukang, totaling 58.55% [4] Management Background - Ding Wenfeng, aged 48, holds a doctoral degree and has extensive experience in drug research and development, having worked in various pharmaceutical companies before leading Weiqi Technology [4][7] Financial Performance - The company's revenue is projected to grow from 135 million yuan in 2022 to 248 million yuan in 2024, with net profits increasing from approximately 35.13 million yuan to 70.64 million yuan during the same period, indicating rapid growth [9]

Core Viewpoint - Marubi has established itself as a leading brand in the eye care segment, achieving significant sales milestones and cultural relevance through its annual "Eye Cream Festival" and collaborations with artists, thereby redefining the standards for domestic eye care products [6][19][28]. Group 1: Brand Recognition and Achievements - Marubi was awarded the title of "First Brand in Domestic Eye Care" by the China Fragrance and Cosmetic Industry Association, highlighting its market leadership and brand strength [16][18]. - The brand has maintained the highest sales in the eye care category for three consecutive years, with its flagship product, the small red pen eye cream, achieving sales of 5 billion [18][19]. - In 2024, Marubi's GMV exceeded 900 million, with an impressive growth rate of 83.9%, further solidifying its position as the leading domestic eye care brand [18]. Group 2: Marketing and Cultural Integration - The 12th "Eye Cream Festival" featured a collaboration with contemporary artist Song Santu, emphasizing the integration of art and culture into the brand's marketing strategy [7][10]. - Marubi's marketing approach has evolved from emotional marketing to emotional engagement, creating a deeper connection with consumers through artistic collaborations [12][14]. - The festival has transformed from a promotional event into a cultural ceremony, enhancing brand identity and consumer engagement [27][28]. Group 3: Product Development and Innovation - Marubi has focused on continuous product innovation, launching multiple iterations of its small red pen eye cream, with the latest version featuring a 25% custom high-concentration peptide formula [22][24]. - The brand has developed a comprehensive product matrix, including key products like the small purple eye cream and butterfly eye mask, to enhance its online presence and sales performance [24]. - Marubi's research and development capabilities have evolved into a fourth-generation system, integrating advanced technologies to ensure product efficacy and safety [27]. Group 4: Strategic Positioning and Market Insights - Marubi's strategy emphasizes systematic capabilities, combining product development, marketing, and consumer trust to create a robust competitive advantage in the eye care market [26][28]. - The brand's long-term commitment to quality and innovation has allowed it to build a strong reputation and consumer loyalty in a highly competitive landscape [19][28]. - Marubi's success illustrates that a brand can thrive in the beauty industry without relying on anxiety-driven narratives, focusing instead on product quality and cultural depth [28][29].

Investment Rating - The report maintains a recommendation for the beauty and personal care industry, highlighting the continued growth of leading domestic brands [2]. Core Insights - The beauty and personal care sector has shown a divergence in performance, with leading domestic brands achieving good growth due to their competitive pricing, differentiated products, and effective online operations [1][10]. - The upcoming 618 shopping festival is expected to further catalyze growth for domestic brands, particularly in the cosmetics sector [1][6]. Summary by Sections Cosmetics - In 2024 and Q1 2025, leading domestic brands continued to show strong growth, with significant revenue increases reported: - Molybdenum Biological: +33% revenue, +32% net profit - Giant Biological: +57% revenue, +42% net profit - Upper Beauty: +62% revenue, +69% net profit [11][13]. - The overall performance of the cosmetics sector is characterized by a mix of growth and decline among various companies, with some like Proya showing resilience in profit despite revenue slowdowns [12][13]. - The report suggests focusing on brands with strong single-product strategies and innovative ingredients, such as Giant Biological and Molybdenum Biological, as well as those with strong brand positioning like Mao Geping [1][6]. Personal Care - The personal care segment has seen robust performance from leading domestic brands, with notable revenue growth in Q1 2025: - Baiya: +30% - Stable Medical: +36% - Hao Yue Care: +42% [6][12]. - The report emphasizes the importance of product upgrades and channel expansion for these brands, which have outperformed OEM companies [1][6]. - The ongoing trend of online expansion and the shift towards mid-to-high-end branding remains strong, with companies like Baiya and Stable Medical showing promising developments [6][12]. Market Trends - The overall market for cosmetics in early 2025 showed a slight increase in retail sales, with a year-on-year growth of 4.0% in the first four months [23]. - Online platforms like Tmall and Douyin have seen varying performance, with Douyin showing higher growth rates in certain categories compared to Tmall [26][29]. Key Brand Performance - Key brands have demonstrated significant growth in both Tmall and Douyin platforms, with notable increases in GMV for brands like Mao Geping and Kefu Mei [33]. - The report highlights the competitive landscape, with domestic brands increasingly capturing market share from international brands due to their pricing and innovative marketing strategies [1][6].

Investment Rating - The report maintains a "Strong Buy" rating for the company [1][8]. Core Views - The company shows strong performance with a projected revenue growth of 33% and a net profit growth of 32% for 2024, continuing into Q1 2025 with revenue growth of 28% and net profit growth of 22% [1][2]. - The dual-brand strategy, featuring the main brand Marubi and the PL brand Lianhuo, is driving growth, with significant contributions from key products like the Marubi Eye Cream and the Golden Needle series [1][3]. - The company is expected to achieve net profits of 445 million, 549 million, and 643 million yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 30%, 23%, and 17% [1][8]. Financial Performance - In 2024, the company achieved a total revenue of 2.97 billion yuan, a year-on-year increase of 33.44%, and a net profit of 342 million yuan, up 31.69% [2][9]. - The main brand Marubi generated revenue of 2.06 billion yuan in 2024, growing by 31.69%, while the PL brand Lianhuo achieved 905 million yuan, a growth of 40.72% [3][9]. - The company's gross margin improved to 73.70% in 2024, up by 3.01 percentage points, attributed to product structure optimization and cost control [7][12]. Product and Channel Analysis - The company’s product categories showed strong performance, with eye care products generating 689 million yuan in revenue, a 60.78% increase, and skincare products reaching 1.13 billion yuan, up 21.60% [3][9]. - Online sales channels contributed significantly, with revenue of 2.54 billion yuan in 2024, reflecting a growth of 35.77%, while offline channels saw a 20.79% increase to 427 million yuan [3][9]. Future Outlook - The company is expected to continue its growth trajectory with a stable cash flow and a focus on product innovation, which is anticipated to contribute to incremental growth [8][9]. - The projected earnings per share (EPS) for 2025 is 1.11 yuan, with a price-to-earnings (PE) ratio of 39.3 [9][12].